Learn From the Experts About Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
 |
Risk-Adapted Treatment of Aggressive B-Cell Lymphomas: Application of Novel Agents |
 |
Risk-Adapted Treatment of Indolent B-Cell Lymphomas: Application of Novel Agents |
 |
Emerging Therapies for Multiple Myeloma |
 |
Emerging Therapies for Hodgkin Lymphoma |
 |
Risk-Adapted Treatment of Acute Myelogenous Leukemia |
 |
Risk-Adapted Treatment of Ph- Myeloproliferative Neoplasms |
|
Learn From the Experts About Clinical Advances and Case Studies in Immune Checkpoint Inhibitors in Oncology
 |
Overview of the Immune System and Immune Checkpoint Targets and their MOAs |
 |
Treatment-Related Issues |
 |
Management of Immune-Related Adverse Events |
 |
Renal Cell Carcinoma |
 |
Non–Small Cell Lung Cancer |
 |
Melanoma |
 |
Mismatch Repair Deficiency/Microsatellite Instability-High Cancers |
 |
Head and Neck Cancer |
 |
Urothelial Carcinoma |
|